The FDA’s recently announced “Roadmap to Reducing Animal Testing in Preclinical Safety Studies” represents a significant shift that could potentially revolutionize the development of monoclonal antibodies, biologics, as well as small molecule drugs. Replacing animal testing in drug development with more effective, human-relevant methods is intended to improve drug safety and accelerate the evaluation process, while reducing animal experimentation, lowering R&D costs and, ultimately, drug prices too. Human-based in vitro models and other new approaches have put organoids and organ-on-chip systems central to the FDA’s implementation of this new initiative.
This Biocompare webinar will explore whether in vitro models are sufficiently developed for widespread use. The presentations will address current capabilities, limitations, and future directions of these cutting-edge technologies. Additionally, how these alternatives might accelerate the drug development timeline will be reviewed.
The webinar features two distinguished experts in the field: Lena Smirnova from Johns Hopkins University, whose research focuses on developing advanced in vitro neurological models, and James Hickman from the University of Central Florida, a pioneer in human-on-a-chip, multi-organ models for a range of indications. They will share their latest work on developing increasingly sophisticated organoid and organ-on-chip systems that better recapitulate human physiology and disease states.
In this webinar, you will learn:
- Implications of replacing animal testing with human-relevant methods such as organoids and organ-on-chip systems.
- The current strengths and limitations of advanced in vitro models for assessing drug safety.
- Ways these emerging technologies could speed up drug development and lower research costs.
- Future advances and applications of organoid and multi-organ chip systems in preclinical studies.
Register now and find out how these advanced systems could complement and perhaps ultimately replace traditional animal testing methods in modern drug development.